Obstructive sleep apnea syndrome after hematopoietic stem cell transplantation in children with mucopolysaccharidosis type I

Article ID	Journal	Published Year	Pages	File Type
10832561	Molecular Genetics and Metabolism	2015	6 Pages	PDF

Abstract

HSCT does not offer long term protection against OSAS in MPS I with OSAS being documented in all patients after a time elapse since HSCT exceeding 10Â years. The potential benefit of additional enzyme replacement therapy needs to be assessed.

Keywords

SDB NEMI WPPSI-R PtcCO2 ODI Central Apnea Index MPS I HSCT OSAS IDUA SpO2 GAG CAI aHI enzyme replacement therapy Obstructive apnea Central apnea OAHI intellectual quotient sleep disordered breathing rapid eye movement sleep REM sleep obstructive sleep apnea syndrome Scheie syndrome Hurler syndrome apnea–hypopnea index oxygen desaturation index Developmental quotient Wechsler Intelligence Scale for Children Mucopolysaccharidosis I ERT PSG Pulse oximetry Polysomnography Wechsler Preschool and Primary Scale of Intelligence Hematopoietic stem cell transplantation Child Glycosaminoglycan

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Biochemistry

Preview

Obstructive sleep apnea syndrome after hematopoietic stem cell transplantation in children with mucopolysaccharidosis type I

Authors

Johan Moreau, Anais Brassier, Alessandro Amaddeo, Benedicte Neven, Catherine Caillaud, Allel Chabli, Marta Fernandez-Bolanos, Jorge Olmo, Vassili Valayannopoulos, Brigitte Fauroux,